JP2023017050A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023017050A5 JP2023017050A5 JP2022197027A JP2022197027A JP2023017050A5 JP 2023017050 A5 JP2023017050 A5 JP 2023017050A5 JP 2022197027 A JP2022197027 A JP 2022197027A JP 2022197027 A JP2022197027 A JP 2022197027A JP 2023017050 A5 JP2023017050 A5 JP 2023017050A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor according
- administered
- decrease
- acceptable salt
- period
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003112 inhibitor Substances 0.000 claims 6
- OBKXEAXTFZPCHS-UHFFFAOYSA-N 4-phenylbutyric acid Chemical compound OC(=O)CCCC1=CC=CC=C1 OBKXEAXTFZPCHS-UHFFFAOYSA-N 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 1
- 230000004323 axial length Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 239000003889 eye drop Substances 0.000 claims 1
- 229960002232 sodium phenylbutyrate Drugs 0.000 claims 1
- VPZRWNZGLKXFOE-UHFFFAOYSA-M sodium phenylbutyrate Chemical compound [Na+].[O-]C(=O)CCCC1=CC=CC=C1 VPZRWNZGLKXFOE-UHFFFAOYSA-M 0.000 claims 1
Claims (8)
- フェニル酪酸又はその薬理学的に許容される塩を有効成分として含有する、屈折値（Ｄ）の低下の抑制剤。
- 前記フェニル酪酸の薬理学的に許容される塩が、フェニル酪酸ナトリウムである、請求項１に記載の抑制剤。
- １日１回投与されるものである、請求項１又は２に記載の抑制剤。
- ３週間以上投与されるものである、請求項１～３のいずれか一項に記載の抑制剤。
- 成長に付随して生じる正常な眼軸長の伸長期間に投与されるための、請求項１～４のいずれか一項に記載の抑制剤。
- 屈折値（Ｄ）の低下が進行する期間に投与されるための、請求項１～５のいずれか一項に記載の抑制剤。
- 小児用である、請求項１～６のいずれか一項に記載の抑制剤。
- 剤形が点眼剤である、請求項１～７のいずれか一項に記載の抑制剤。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024002286A JP2024026709A (ja) | 2017-03-06 | 2024-01-11 | マウス近視誘導モデル及び近視予防・抑制のための小胞体ストレス抑制剤 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2017041349 | 2017-03-06 | ||
| JP2017041349 | 2017-03-06 | ||
| JP2021038816A JP7236753B2 (ja) | 2017-03-06 | 2021-03-11 | マウス近視誘導モデル及び近視予防・抑制のための小胞体ストレス抑制剤 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021038816A Division JP7236753B2 (ja) | 2017-03-06 | 2021-03-11 | マウス近視誘導モデル及び近視予防・抑制のための小胞体ストレス抑制剤 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024002286A Division JP2024026709A (ja) | 2017-03-06 | 2024-01-11 | マウス近視誘導モデル及び近視予防・抑制のための小胞体ストレス抑制剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023017050A JP2023017050A (ja) | 2023-02-02 |
| JP2023017050A5 true JP2023017050A5 (ja) | 2023-09-26 |
| JP7424676B2 JP7424676B2 (ja) | 2024-01-30 |
Family
ID=63448602
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019504597A Active JP6637217B2 (ja) | 2017-03-06 | 2018-03-06 | 近視予防又は抑制剤、マウス近視誘導モデルの作製方法、及び、近視予防又は抑制医薬スクリーニング方法 |
| JP2019202287A Active JP6856275B2 (ja) | 2017-03-06 | 2019-11-07 | 近視予防、治療又は抑制用点眼剤 |
| JP2021038816A Active JP7236753B2 (ja) | 2017-03-06 | 2021-03-11 | マウス近視誘導モデル及び近視予防・抑制のための小胞体ストレス抑制剤 |
| JP2022197027A Active JP7424676B2 (ja) | 2017-03-06 | 2022-12-09 | マウス近視誘導モデル及び近視予防・抑制のための小胞体ストレス抑制剤 |
| JP2024002286A Pending JP2024026709A (ja) | 2017-03-06 | 2024-01-11 | マウス近視誘導モデル及び近視予防・抑制のための小胞体ストレス抑制剤 |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019504597A Active JP6637217B2 (ja) | 2017-03-06 | 2018-03-06 | 近視予防又は抑制剤、マウス近視誘導モデルの作製方法、及び、近視予防又は抑制医薬スクリーニング方法 |
| JP2019202287A Active JP6856275B2 (ja) | 2017-03-06 | 2019-11-07 | 近視予防、治療又は抑制用点眼剤 |
| JP2021038816A Active JP7236753B2 (ja) | 2017-03-06 | 2021-03-11 | マウス近視誘導モデル及び近視予防・抑制のための小胞体ストレス抑制剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024002286A Pending JP2024026709A (ja) | 2017-03-06 | 2024-01-11 | マウス近視誘導モデル及び近視予防・抑制のための小胞体ストレス抑制剤 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20200150457A1 (ja) |
| EP (1) | EP3593817A4 (ja) |
| JP (5) | JP6637217B2 (ja) |
| KR (1) | KR20190126365A (ja) |
| CN (3) | CN115645535A (ja) |
| WO (1) | WO2018164113A1 (ja) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113164421A (zh) * | 2018-12-18 | 2021-07-23 | 参天制药株式会社 | 含有4-苯基丁酸的老视的治疗或预防剂 |
| TW202038966A (zh) * | 2018-12-18 | 2020-11-01 | 日商參天製藥股份有限公司 | 包含熊去氧膽酸之老花眼之治療或預防劑 |
| EP3934754A4 (en) * | 2019-03-08 | 2022-11-23 | The Regents Of The University Of California | COMPOSITIONS AND METHODS FOR TREATING RESPIRATORY FAILURE |
| CA3204753A1 (en) * | 2020-12-11 | 2022-06-16 | Tsubota Laboratory, Inc. | Eyedrops for inhibiting myopia progression in children and screening method for inhibitor of myopia progression in children |
| IL303511A (en) | 2020-12-11 | 2023-08-01 | Tsubota Lab Inc | Eye drops for the treatment of scleral thinning and a filtration method for a therapeutic agent of scleral thinning |
| CN112970666B (zh) * | 2021-02-04 | 2023-02-03 | 复旦大学附属眼耳鼻喉科医院 | 一种简便式动物近视诱导装置及制作方法 |
| JP2024069730A (ja) * | 2021-03-16 | 2024-05-22 | 慶應義塾 | 網膜変性抑制用組成物 |
| TW202340723A (zh) * | 2022-01-25 | 2023-10-16 | 日商坪田實驗室股份有限公司 | 藉由藥劑點眼而導致之近視誘導模型 |
| TW202400133A (zh) * | 2022-03-25 | 2024-01-01 | 日商坪田實驗室股份有限公司 | 水性組成物 |
| WO2023210657A1 (ja) * | 2022-04-26 | 2023-11-02 | 株式会社坪田ラボ | 近視を予防または治療するための方法および組成物 |
| WO2024048697A1 (ja) * | 2022-08-31 | 2024-03-07 | 国立大学法人京都大学 | 化合物、小胞体ストレス抑制剤、医薬品、眼科用剤、点眼薬、組成物、化合物の製造方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2400803A1 (en) | 2000-01-18 | 2001-07-26 | Richard A. Stone | Ocular growth and nicotinic antagonists |
| CN1191074C (zh) * | 2002-09-18 | 2005-03-02 | 王力 | 熊胆粉滴眼液及其制备方法 |
| MXPA03011987A (es) | 2003-12-19 | 2005-06-23 | Osio Sancho Alberto | Metodo para el tratamiento de la presbicia induciendo cambios en el poder y fisiologia corneal. |
| AU2005284798B2 (en) * | 2004-09-15 | 2012-02-02 | The President And Fellows Of Harvard College | Reducing ER stress in the treatment of obesity and diabetes |
| EP2319539A4 (en) * | 2008-07-24 | 2012-03-28 | Univ Osaka | PROPHYLACTIC OR THERAPEUTIC AGENT FOR AXIAL MYOPIA |
| CA2794153C (en) * | 2010-03-25 | 2018-01-02 | Glaxosmithkline Llc | Substituted indoline derivatives as perk inhibitors |
| UY33288A (es) | 2010-03-25 | 2011-10-31 | Glaxosmithkline Llc | Derivados de indolina inhibidores de la proteina quinasa r del reticulo endoplasmatico |
| US8962686B2 (en) * | 2010-04-28 | 2015-02-24 | The Chinese University Of Hong Kong | Method and medication for prevention and treatment of ocular hypertension and glaucoma |
| US8951729B2 (en) * | 2011-01-14 | 2015-02-10 | University Of Washington Through Its Center For Commercialization | Methods for diagnosing and treating eye-length related disorders |
| WO2013025840A1 (en) * | 2011-08-15 | 2013-02-21 | Massachusetts Eye And Ear Infirmary | Methods for preserving photoreceptor cell viability following retinal detachment |
| WO2015056180A1 (en) * | 2013-10-15 | 2015-04-23 | Glaxosmithkline Intellectual Property (No.2) Limited | Indoline derivatives as inhibitors of perk |
| EP3064222B1 (en) | 2013-10-31 | 2020-10-21 | Kyoto Prefectural Public University Corporation | Therapeutic drug comprising tgf-beta signal inhibitor for diseases related to endoplasmic reticulum cell death in corneal endothelium |
| WO2016171282A1 (ja) * | 2015-04-24 | 2016-10-27 | 学校法人慶應義塾 | 近視予防剤及び近視進行抑制剤 |
| CN112599133A (zh) | 2020-12-15 | 2021-04-02 | 北京百度网讯科技有限公司 | 基于车辆的语音处理方法、语音处理器、车载处理器 |
-
2018
- 2018-03-06 CN CN202211310191.2A patent/CN115645535A/zh active Pending
- 2018-03-06 JP JP2019504597A patent/JP6637217B2/ja active Active
- 2018-03-06 KR KR1020197029237A patent/KR20190126365A/ko active IP Right Grant
- 2018-03-06 CN CN202211310272.2A patent/CN115645536A/zh active Pending
- 2018-03-06 CN CN201880016406.5A patent/CN110392579B/zh active Active
- 2018-03-06 EP EP18764652.6A patent/EP3593817A4/en active Pending
- 2018-03-06 WO PCT/JP2018/008554 patent/WO2018164113A1/ja unknown
-
2019
- 2019-09-05 US US16/561,776 patent/US20200150457A1/en active Pending
- 2019-11-07 JP JP2019202287A patent/JP6856275B2/ja active Active
-
2021
- 2021-03-11 JP JP2021038816A patent/JP7236753B2/ja active Active
-
2022
- 2022-12-09 JP JP2022197027A patent/JP7424676B2/ja active Active
-
2024
- 2024-01-11 JP JP2024002286A patent/JP2024026709A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023017050A5 (ja) | ||
| JP2020023574A5 (ja) | 近視予防、治療又は抑制用点眼剤、及び、小胞体ストレス抑制用点眼剤 | |
| JP7424676B2 (ja) | マウス近視誘導モデル及び近視予防・抑制のための小胞体ストレス抑制剤 | |
| ES2518418T3 (es) | Composiciones de vasoconstricción y métodos de uso | |
| JP6666487B2 (ja) | ドライアイ治療用点眼剤 | |
| SI2760821T1 (en) | A salt salt of an anti-inflammatory substituted cyclobutenedione compound | |
| RU2632107C2 (ru) | Пероральная фармацевтическая композиция для профилактики или лечения синдрома "сухого глаза", содержащая ребамипид или его предшественник | |
| ES2335181B1 (es) | Combinacion de sustancias activas. | |
| JP2015526467A5 (ja) | ||
| JP2021046394A5 (ja) | ||
| JP2021006548A5 (ja) | ||
| JP2017529377A5 (ja) | ||
| JP2019530729A5 (ja) | ||
| AU2012265231B2 (en) | Nasal pharmaceutical formulation | |
| US20180125792A1 (en) | Non-steroidal anti-inflammatory drugs for cough | |
| RU2018102746A (ru) | Офтальмологическая фармацевтическая композиция | |
| CA2964684A1 (en) | Composition for the treatment of conditions involving muscular pain | |
| ES2629103T3 (es) | Formulación en polvo de valganciclovir | |
| JP2013519695A5 (ja) | ||
| US20130281506A1 (en) | Combination of a non-steroidal anti-inflammatory drug with an anti-histaminic drug intended for ophthalmic use | |
| EP1496884B1 (fr) | Association d'un antithrombotique et d'aspirin et son utilisation pour le traitement des maladies thrombotiques atherosclereuses | |
| AU725697B2 (en) | Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of dementia | |
| JP2019511996A5 (ja) | ||
| WO2011067663A1 (en) | Pharmaceutical preparations comprising phloroglucinol and/or derivatives thereof and some non-steroidal anti-inflammatory drugs and their use in the treatment and/or prevention of pain syndromes of the feminine genital system | |
| RU2020124742A (ru) | Фармацевтический препарат, содержащий пиридиламиноуксусную кислоту |